Integrated DNA Technologies Bolsters Leadership Team, Adds New Global Head of Commercial

Life sciences veteran will continue to drive commercial excellence, build on company’s legacy to propel future strategic growth

Global genomics solutions provider Integrated DNA Technologies (IDT) announced it has appointed Linda De Jesus as vice president and general manager, global head of commercial, adding a new leader to the company’s executive team. De Jesus brings over 20 years of international life sciences leadership experience from her diverse career in general management and commercial functions with a track record of successful execution for high-growth businesses spanning pharmaceutical, biopharma, biotechnology and academia. As IDT Global VP and General Manager of Commercial, De Jesus will focus on elevating IDT’s market position and driving future strategic business growth for its expanding portfolio in Genomic Medicine comprised of next generation sequencing (NGS), CRISPR genome editing, synthetic biology and PCR solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005299/en/

Global genomics solutions provider Integrated DNA Technologies (IDT) announced it has appointed Linda De Jesus as vice president and general manager, global head of commercial, adding a new leader to the company’s executive team. (Photo: Business Wire)

“Linda’s tenure in life sciences—coupled with her longstanding history of driving commercial excellence and leading multiple business units across diverse technologies and market segments—will add significant value to IDT’s strategic vision as we continue to accelerate our business strategy, add new capabilities, and serve our customers to enable the greatest genomic breakthroughs,” said IDT President Demaris Mills. “We are pleased that Linda has chosen IDT for the next chapter of her career, committing her customer-centric and pragmatic approach to deliver on IDT’s growth objectives and know that she will reinforce the collaborative agility that has been the hallmark of IDT’s success for more than 30 years.”

Prior to joining IDT, De Jesus was at Azenta Life Sciences where she served as senior vice president and chief commercial officer. In that capacity, she was responsible for the company’s global commercial functions and the integration of go-to-market strategies. She spearheaded the company’s rebranding efforts from Brooks Life Sciences to Azenta Life Sciences, overseeing the launch of its new corporate identity and other high-profile activation efforts. Prior to Azenta, De Jesus was VP and general manager for the Chromatography and Mass Spectrometry division of Thermo Fisher Scientific where she was responsible for a group of business units across consumables, instruments and software. While there, she held multiple senior executive positions including leading one of the largest global commercial roles responsible for $2.5 billion USD and 2,400 employees. De Jesus has an Executive MBA from University of Connecticut, School of Business and a Bachelor of Science in Chemistry from Colombia University.

“It is an incredible honor for me to join IDT and serve a company with such a proud history of innovation. Over the past decades, IDT has set the standard for genomics excellence, and has earned a solid reputation for its world-class products and solutions,” said De Jesus. “We are at an inflection point with new market dynamics and technologies. We now stand at the forefront of innovations in genomic medicine and solutions to shape the industry in advancing therapeutics. I look forward to working with our associates, customers, and partners to accelerate the pace of genomics and enable researchers to rapidly move from the lab to life-changing advancements.”

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP* services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as an industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, visit www.idtdna.com and follow the company on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. *GMP refers to products manufactured under ISO 13485: 2016 QMS. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005299/en/